Hr. Langhammer et al., DETECTION IN RECURRENT BREAST-CANCER BY C A 15-3 AND CEA - INFLUENCE OF LOCALIZATION AND EXTENT OF METASTASES, Tumordiagnostik & Therapie, 15(3), 1994, pp. 96-103
This retrospective study was designed in order to evaluate sensitivity
, specifity, and accuracy of CA 15-3 and CEA serum levels as well as t
heir combination in the follow-up of 2224 breast cancer patients (595
with proven metastases) depending on die localization and extent of me
tastatic diseases. At an equivalent 97 % specificity, a higher sensiti
vity of 60.2 % was determined for CA 15-3 in comparison with 47.9 % fo
r CEA (p < 0.01). The combined determination of both marker levels inc
reased the sensitivity by 11.4 %. The significantly higher sensitivity
of CA 15-3 compared to CEA was only seen in patients with bone metast
ases but not in patients with visceral or pulmonal metastases or in lo
coregional recurrence. The sensitivity of CA 15-3 in bone metastases w
as higher for extensive as well as for minimal metastatic spread. The
sensitivity of CEA, CA 15-3, and their combination in 365 patients was
significantly lower for the detection of a locoregional recurrence (1
8.2 %, 21.2 %, 31.8 %, respectively) compared with patients with isola
ted distant metastases. With the exception of CEA levels in lung metas
tases the levels of CEA and Ca 15-3 were significantly lower compared
to other localizations of distant metastases. The sensitivity was 11.9
%, 28.6 %, and 33.3 % in 299 patients with minimal spread of metastas
es into only one organ and correlated well with the extent of sensitiv
ities (34.2 %, 39.5 %, 57.9 %) in patients with moderate metastatic sp
read. Significantly highest sensitivities (54.8 %, 66.7 %, 78.5 %) wer
e found for patients with extensive metastatic spread. This correlatio
n between the sensitivity and the extent of the metastatic spread was
also confirmed in 215 patients with metastases limited to the bone. In
this group the lowest sensitivities (10.3 %, 34.5 %, 37.9 %) were fou
nd in minimal metastatic disease. The correlation of the serum levels
of CEA with the extent of metastatic spread was lower compared to CA 1
5-3. Therefore, CA 15-3 seems to be more useful for the determination
of the metastatic spread. The low sensitivity of CA 15-3 and CEA for t
he detection of locoregional recurrence and minimal metastatic spread
(30-40 %) is a limiting factor for their use in follow-up. For the det
ection or the rule-out of beginning distant metastasis, especially of
bone metastases, these sensitivity levels seem to be too low.